Medication Guide App

New Data Highlighting Abraxane as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO

LOS ANGELES--(BUSINESS WIRE)--May 30, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that multiple studies of ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. Data will be presented from studies which highlight the potential utility of ABRAXANE (ABI-007) as a single-agent and in combination for the treatment of breast, lung and ovarian cancers.

An updated analysis of the study titled "A Randomized Phase II Study of Weekly or Every 3 Weeks ABI-007 vs. Every 3 Weeks Taxotere(R) as First Line Therapy of Stage IV Metastatic Breast Cancer" (Abstract 1032) will be presented as a poster on Saturday, June 2, 2007 from 8 a.m. to 12 p.m. (Room S403), with a poster discussion following from 12 p.m. to 1 p.m., S406 (Vista Room). The updated analysis of the Phase II study evaluates first-line treatment ABRAXANE given weekly and every three weeks compared to Taxotere(R) (docetaxel) dosed every three weeks in patients with metastatic breast cancer. Interim results of this study were presented at the San Antonio Breast Cancer Symposium in December 2006.

Abraxis is continuing to expand its clinical experience with ABRAXANE and its potential in treating multiple tumor types as a single agent and in combination. Data from company and investigator-sponsored studies in breast, lung and ovarian cancer will be presented during the poster presentations including:

BREAST CANCER

Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC) (Abstract 1038)

Poster Presentation: Saturday, June 2, 8:00 a.m. to 12:00 p.m., Room S403

Poster Discussion: Saturday, June 2, 12 p.m. to 1 p.m., Room S406 (Vista Room)

NCCTG Phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC) (Abstract 1048)

Poster Presentation: Saturday, June 2, 2 p.m. to 6 p.m., S Hall A2

Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC): Interim Results (Abstract 1053)

Poster Presentation: Saturday, June 2, 2 p.m. to 6 p.m., S Hall A2

Randomized phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as 1st-line therapy for HER2 negative metastatic breast cancer: An initial interim safety report (Abstract 1104)

Poster Presentation: Saturday, June 2, 2 p.m. to 6 p.m., S Hall A2

LUNG CANCER

Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC) (Abstract 7659)

Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., S Hall A2

An open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC) (Abstract 7610)

Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., S Hall A2

OVARIAN CANCER

Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer (Abstract 5525)

Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., Room E451a

Poster Discussion: Sunday, June 3, 11 a.m. to 12 p.m., Room E354a

About ABRAXANE

The U.S. Food and Drug Administration approved ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. For the full prescribing information for ABRAXANE, please visit www.abraxane.com.

ABRAXANE was developed by Abraxis BioScience, Inc. ABRAXANE is marketed in the United States under a co-promotion agreement between Abraxis BioScience, Inc. and AstraZeneca Pharmaceuticals LP.

About Abraxis BioScience, Inc.

Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com.

Taxotere(R) is a registered trademark of Sanofi-Aventis.

Contact

Investors and Media:
Abraxis BioScience, Inc.
Christine Cassiano, 310-405-7417

Posted: May 2007

View comments

Hide
(web1)